$MSB #Mesoblast Ltd. Mesoblast - COVID-19 ARDS Phase III readout later this year: Mesoblast has initiated a 300-patient randomized, controlled Phase III trial of remestemcel-L (Ryoncil for the acute graft versus host disease (aGvHD)… https://t.co/BziXmXKmsC #equity #stocks https://t.co/XRNcvWGzzm